Helicobacter pylori: changing patterns of ulcer disease and antibiotic resistance.
Katelaris
P H
PH
D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D000897:Anti-Ulcer Agents / Q000494:pharmacology / Q000627:therapeutic use; D001315:Australia / Q000453:epidemiology; D017291:Clarithromycin / Q000494:pharmacology / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D016481:Helicobacter Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008795:Metronidazole / Q000494:pharmacology / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology
D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D008795:Metronidazole; D017291:Clarithromycin